Table 1.
Patients' demographic and clinical characteristics
| Demographic characteristics | Overall (n = 112) | Once daily (n = 31) | Four times daily (n = 81) | |||
|---|---|---|---|---|---|---|
| n | (%) | n | (%) | n | (%) | |
| Gender | ||||||
| Male | 53 | (47.3) | 14 | (45.2) | 39 | (48.1) |
| Female | 59 | (52.7) | 17 | (54.8) | 42 | (51.9) |
| Diagnosis | ||||||
| Malignancies | 74 | (66.1) | 22 | (71.0) | 52 | (64.2) |
| AML | 34 | (30.4) | 7 | (22.6) | 27 | (33.3) |
| MDS | 19 | (17.0) | 1 | (3.2) | 18 | (22.2) |
| ALL | 8 | (7.1) | 2 | (6.5) | 6 | (7.4) |
| Neuroblastoma | 12 | (10.7) | 12 | (38.7) | 0 | (0.0) |
| MPS | 1 | (0.9) | 0 | (0.0) | 1 | (1.2) |
| Non‐Malignancies | 38 | (33.9) | 9 | (29.0) | 29 | (35.8) |
| Immunodeficiencies | 10 | (8.9) | 0 | (0.0) | 10 | (12.3) |
| Hemoglobinopathy | 16 | (14.3) | 7 | (22.6) | 9 | (11.1) |
| Metabolic diseases | 7 | (6.3) | 2 | (6.5) | 5 | (6.2) |
| Hemophagocytic syndrome | 5 | (4.5) | 0 | (0.0) | 5 | (6.2) |
| Conditioning regimen | ||||||
| BuCy | 91 | (81.3) | 17 | (54.8) | 74 | (91.4) |
| BuCyVP16 | 8 | (7.1) | 0 | (0.0) | 8 | (9.9) |
| BuMel | 14 | (12.5) | 12 | (38.7) | 2 | (2.5) |
| BuCyMel | 1 | (0.9) | 1 | (3.2) | 0 | (0.0) |
| BuMelAraC | 1 | (0.9) | 1 | (3.2) | 0 | (0.0) |
| Number of HSCT | ||||||
| 2 | 7 | (6.3) | 0 | (0.0) | 7 | (8.6) |
| 3 or more | 1 | (0.9) | 0 | (0.0) | 1 | (1.2) |
| Ethnic groups | ||||||
| Caucasian | 94 | (83.9) | 65 | (80.2) | 29 | (93.5) |
| African | 12 | (10.7) | 10 | (12.3) | 2 | (6.5) |
| Other | 6 | (5.4) | 6 | (7.4) | 0 | (0.0) |
| Weight adequacy a | ||||||
| Overweight | 14 | (12.5) | 1 | (4.3) | 13 | (23.2) |
| Obesity | 7 | (6.3) | 1 | (4.3) | 6 | (10.7) |
| GSTA1 diplotype group | ||||||
| Group 1 | 16 | (14.3) | 6 | (19.4) | 10 | (12.3) |
| Group 2 | 80 | (71.4) | 20 | (64.5) | 60 | (74.1) |
| Group 3 | 16 | (14.3) | 5 | (16.1) | 11 | (13.6) |
| Age (years) | ||||||
| Median | 5.4 | 4.8 | 5.6 | |||
| Minimum | 0.1 | 0.4 | 0.1 | |||
| Maximum | 20 | 16 | 20 | |||
AML, acute myeloid leukemia; MDS, myelodisplastic syndrome; ALL, acute lymphoblastic leukemia; MPS, myeloproliferative disease; Cy, cyclophosphamide; VP16, etoposide; Mel, melphalan; AraC, cytarabine.
a
Evaluated according to Barlow et al. 45 only in children older than 2 years old